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Abstract. 
The association between sarcoidosis and lymphoproliferative diseases is well-recognized. 
As fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is increasingly 
utilized in lymphoma staging, it is important for clinicians to be aware of lymphoma mimickers 
on FDG-PET. Here we describe two patients with diffuse large B-cell lymphoma who present-
ed with high muscular FDG-uptake. The first patient had histologically proven concomitant 
muscular sarcoidosis, while the second patient had primary skeletal muscle lymphoma. 
FDG-PET is of limited utility in discerning sarcoidosis and lymphoma, as both lesions are 
FDG-avid. Magnetic resonance imaging may provide clues to differentiate these two entities 
non-invasively. The “3 stripes” and “dark star” signs are characteristic for muscular sarcoidosis, 
whereas muscular lymphoma usually demonstrates homogenous gadolinium enhancement. 
Nevertheless, histological examination remains the gold standard in distinguishing hese two 
diseases. In conclusion, while FDG-PET may be useful in monitoring disease extent and activ-
ity of both sarcoidosis and lymphoma, and MRI may provide additional diagnostic information, 
biopsy is still recommended when clinical decision-making dictates confirmatory diagnosis. 
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中文摘要 
  近年來，正子掃描廣泛用於淋巴瘤的分期檢查。因此，與淋巴瘤在正子掃瞄上有相
似表現的疾病，可能會造成臨床分期的錯誤，進而影響治療策略。過去已有文獻報導淋
巴瘤與類肉瘤症並存的案例，稱為類肉瘤—淋巴瘤症候群。本文描述兩位患有瀰漫性大 B
細胞淋巴瘤的病人，在正子掃描下，其骨骼肌均表現高葡萄糖吸收量。第一位病人診斷
為淋巴瘤，肌肉病灶經切片後，證實為合併肌肉型類肉瘤症；第二位病人則是原發性肌
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肉淋巴瘤。核磁共振攝影可用以協助區辨肌肉型類肉瘤症與原發性肌肉淋巴瘤：典型的
肌肉型類肉瘤症在核磁共振上表現「三斑」與「暗星」徵象，原發性肌肉淋巴瘤則表現
均勻的高顯影劑顯影。雖然核磁共振掃瞄可輔助鑑別診斷，但組織學檢查仍為區辨標準。
在治療類肉瘤症與淋巴瘤的病人，正子掃瞄可用以評估疾病範圍與活性，核磁共振可提
供額外的診斷資訊，但當病人的治療計劃會因診斷而改變時，仍應進行組織切片做確切
的區辨。 
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INTRODUCTION 
There is growing evidence demonstrating the as-
sociation between sarcoidosis and lymphoproliferative 
diseases [1,2]. The coexistence of sarcoidosis and 
lymphoma, the "sarcoidosis-lymphoma syndrome", is 
difficult to diagnose because of overlapping clinical 
and radiological features [1]. Both sarcoidosis and 
lymphoma show fluorine-18 fluorodeoxyglucose 
(FDG)-avid lesions in positron emission tomography 
(PET) [2]. PET has gained an increasingly important 
role in the staging and follow-up of lymphoma. On the 
other hand, PET has been utilized to monitor disease 
activity and to follow treatment response in sarcoido-
sis [3]. It is highly possible to mistake sarcoid lesions 
for lymphoma, or vice versa, on FDG-PET alone. 
Here we present two cases of lymphoma with high 
muscular FDG uptake due to distinct etiology. The 
first patient was diagnosed to have diffuse large B-cell 
lymphoma (DLBCL) of the nasopharynx concurrently 
with histologically proven muscular sarcoidosis, 
whereas the second patient had primary skeletal mus-
cle DLBCL. The radiological similarity of muscular 
sarcoidosis and muscular lymphoma is described and 
the possible means to differentiate these two disease 
entities are discussed. 
 
CASE REPORTS 
 
Case 1 
A 63-year-old woman visited our hospital for 
evaluation of an enlarging right neck mass noted for 3 
months. She has no underlying diseases except for 
multinodular goiter. She reported no fever, night 
sweats, nasal obstruction, or epistaxis, but her body 
weight decreased from 52 kilograms to 44 kilograms 
in 5 months. Head and neck MRI showed bilateral 
cervical lymphadenopathy, with the largest right level 
II lymph node measuring 3.5 cm, as well as thickened 
left nasopharyngeal mucosa. Nasopharyngeal biopsy 
revealed diffuse large B-cell lymphoma (DLBCL), 
positive for CD20. A PET scan demonstrated an in-
tensive FDG uptake in the nasopharynx and bilateral 
enlargement of cervical lymph nodes (SUVmax=14.1), 
mild to moderate hot spots in hilar nodes and lungs on 
both sides (SUVmax = 4.0), and patchy linear foci of 
mild to moderately increased metabolism in the mus-
cles of upper and lower extremities of both sides, 
trunk, and buttock (SUVmax=7.8) (Figure 1A).   
Because the patchy FDG-avid muscular lesions are 
unusual for lymphoma, further investigation was ar-
ranged. The muscular lesions could not be palpated on 
physical examination and the patient reported no my-
algia or weakness. The creatinine kinase level was 25 
U/L (reference 30-223 U/L). MRI of both lower ex-
tremities detected numerous intramsucular lesions in 
parallel with muscle fibers. These lesions were iso-
intense on T1-weighted images and hyperintense on 
T2-weighted images, and showed rim gadolinium en-
hancement with dark-star centers (Figure 1B-D). 
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Figure 1. Images of Case 1. (A) FDG-PET in maximal intensity projection mode. In addition to the intense FDG 
uptake at the nasopharynx and bilateral cervical lymph node involvement illustrating lymphoma extent, 
the characteristic linear “tiger man” uptake pattern of muscular sarcoidosis in the striated muscles of 
the extremities. (B) T2-weighted axial MR image at the level of mid thigh. There were numerous   
hyperintense intramuscular lesions. (C) gadolinium (Gd)-enhanced T1-weighted axial image with 
fat-saturation at the same level, showing rim enhancement and a central “dark star” sign, which   
manifests as a “3 stripes” sign (i.e. a central low signal stripe sandwiched by two outer parallel stripes 
of contrast enhancement) on (D) Gd-enhanced T1-weighted coronal image 
 
 
Muscle biopsy of the left thigh showed non-caseating 
granulomatous inflammation composed of aggregates 
of tightly clustered epithelioid cells and giant cells 
(Figure 2). Staining for acid-fast bacilli was negative, 
and thus the lesion was compatible with sarcoidosis. 
The final diagnosis was DLBCL involving the naso-
pharynx and cervical lymph nodes, stage IIB, with 
concomitant pulmonary and muscular sarcoidosis. The 
patient underwent R-CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisolone) chem-
otherapy uneventfully. 
  
Case 2 
A 65-year-old man visited to our hospital with 
progressive left thigh swelling for 3 months. He re-
ported no fever, weight loss, or night sweats. Physical 
examination revealed swelling of the left medial thigh. 
MRI of the lower extremities revealed an enlarged left 
tensor fasciae latae and hamstring muscles, with iso-
intensity on T1-weighted images and hyperintensity 
on T2-weighted images (Figure 3B-C). There was 
mild contrast enhancement after gadolinium admin-
istration (Figure 3D). CT-guided biopsy of the left 
thigh mass revealed histologically a DLBCL with a  
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Figure 2. Hematoxylin-eosin staining (400X) shows-
ing non-caseating granulomatous inflam-
mation composed of epithelioid cells and 
giant cells in a background of fibrous tissue 
 
 
positive stain for CD20. FDG-PET scan showed a 
large focal hot area in the left pelvic wall and left 
thigh muscle (SUVmax=14.31; image not shown). 
The diagnosis was primary skeletal muscle DLBCL, 
stage IVE, with extensive muscular involvement. The 
patient underwent six courses of R-CHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine, dexame-
thasone) chemotherapy, but obtained only partial re-
sponse. The disease subsequently progressed to in-
volve the brain, nuchal muscles, and pelvic cavity 
(Figure 2A). Salvage chemotherapy comprising of 
R-ICE (rituximab, ifosfamide, cisplatin, and etoposide) 
was administered. He developed, however, status epi-
lepticus secondary to extensive brain metastasis and 
subsequently died of sepsis 7 months after the initial 
diagnosis.  
 
DISCUSSION 
The association between sarcoidosis and lympho-
ma has been well described in the pliterature [1,2,4]. 
Sarcoid patients have a 5.5 fold increase in risk of 
developing malignant lymphoproliferative diseases [1]. 
Both Hodgkin’s lymphoma and non-Hodgkin’s lym-
phoma have been found in patients with sarcoidosis, 
and lymphoma of the T-cell lineage has been reported 
as well [2,4]. The mechanism underlying this associa-
tion remains unclear, but immune dysregulation is the 
most prevailing hypothesis [4]. 
In sarcoidosis, myopathy occurs in 50 to 80% of 
patients, while only 1.4% are symptomatic [5,6]. 
Symptomatic sarcoid myopathy is classified into three 
forms, namely, chronic myopathy, acute myositis, and 
lesions of nodular type [6-8]. In our first case, the pa-
tient’s sarcoid myopathy was entirely asymptomatic, 
and was only an incidental finding during staging 
workup for lymphoma. For symptomatic sarcoid my-
opathy, a steroid is the mainstay of treatment [7,9].  
Primary skeletal muscular lymphoma is a rare 
disease, predominantly involving the lower extremi-
ties. Muscular involvement of lymphoma may develop 
through three different mechanisms. Most commonly 
it is caused by hematogenous or lymphatic dissemina-
tion. It can also occur via direct extension from adja-
cent structures such as bone or lymph nodes. The third 
pathway, as a primary extranodal disease, is the rarest, 
accounting for only 0.5% of all extranodal lymphomas 
[10]. The clinical manifestation of muscular lympho-
ma is enlargement of the involved muscles, associated 
with or without pain. The most common site of mus-
cular involvement is the lower extremity, representing 
50% of cases. Treatment generally consists of chemo-
therapy with or without adjuvant radiotherapy [11]. In 
our second case, the patient developed primary skele-
tal muscle lymphoma of the thigh, which initially re-
sponded to first line chemotherapy but rapidly re-
curred with dissemination to the central nervous sys-
tem. Data on the prognosis of muscular lymphoma are 
sparse due to its rare occurrence, but the prognosis has 
generally been regarded poor [11]. 
Both sarcoidosis and lymphoma are 18F-FDG- 
avid on PET. Our first patient’s thick linear FDG up-
take predominantly involved the lower extremity 
muscles, which was consistent with the "tiger man 
sign" designated for the PET pattern of sarcoid myo-
pathy [12,13]. In contrast, the FDG uptake of muscu-  
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Figure 3. Images of Case 2. (A) FDG-PET in maximal intensity projection mode, showing nodular intense   
hypermetabolic areas involving the left thigh, pelvic cavity, and right nuchal muscles. (B) T1-weighted 
axial MR image at the level of mid thigh, showing isointense left hamstring muscular enlargement. (C) 
T2-weight image at the same level. The involved muscles showed hyperintensity. (D) Gd-enhanced 
T1-weighted image with fat-saturation, showing mild homogeneous contrast enhancement. (E) 
Gd-enhanced T1-weighted image with fat-saturation after six courses of R-CHOP chemotherapy, 
showing resolved intramuscular mass with faint traces of contrast enhancement 
 
 
lar lymphoma is intense and homogenous in our se-
cond patient. Differentiating sarcoid lesions from ma-
lignancy on PET is difficult. Some researchers have 
suggested that the SUV value of ≥ 13 is more specific 
for malignancy, especially for aggressive lymphomas. 
In our first patient, the FDG activity in the lymphoma 
foci (SUVmax 14.1) was indeed more intense than in 
tissues harboring sarcoidosis (SUVmax 7.8). However, 
sarcoid lesions can have SUVs approaching that of 
aggressive lymphoma, and FDF uptake intensity alone 
should not be regarded reliable in distinction [4,14,15]. 
On the other hand, the pattern of FDF uptake may 
provide clues for differentiation: streaky and dotted 
uptake characterizes sarcoid myopathy while homo-
geneous uptake is a feature of lymphoma. However, 
this distinction is not definitive, and early stage dis-
ease might not present with a typical uptake pattern. 
Therefore, PET is of limited utility in distinguishing 
sarcoidosis from lymphoma. 
MRI is currently the most useful image modality 
to distinguish sarcoid myopathy from muscular lym-
phoma. Nodular type sarcoid myopathy usually shows 
high signal intensity on T2-weighted images and pre-
sents with rim enhancement on contrast-enhanced 
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images. The "dark star" and the "3 stripes" signs are 
typical patterns found on T2-weighted or contrast- 
enhanced T1-weighted images, in axial and coronal 
views, respectively. These signs correspond to the le-
sion’s rim-enhancing nature, and reflect the fibrotic 
center resulting from longstanding inflammation with 
surrounding active granulomatous inflammation [8, 
16,17]. The MRI of our first patient’s thighs was con-
sistent with nodular type muscular sarcoidosis, and the 
diagnosis was confirmed by a histological study. 
Conversely, lymphoma of the skeletal muscle usually 
shows muscular enlargement due to the presence of 
soft tissue mass, and is iso- to hyperintense on T1- and 
T2-weighted images. They usually demonstrate ho-
mogeneous gadolinium enhancement [18,19]. Our 
second patient had prominent enlargement of the left 
hamstring muscles on MRI, with homogenous but 
mild gadolinium enhancement. After six cycles of 
R-CHOP chemotherapy, the intramuscular mass re-
solved with only faint residual contrast enhancement.  
In summary, we have presented a case of concom-
itant muscular sarcoidosis and DLBCL of the naso-
pharynx and a case of primary skeletal muscle 
DLBCL. Both muscular sarcoidosis and muscular 
lymphoma show high FDG uptake, and is difficult to 
differentiate on a PET scan alone. MRI may provide 
valuable information in differentiating these two enti-
ties, and has the advantage of being noninvasive and 
free of radiation. However, when suspicious lesions 
develop in a patient with known sarcoidosis, or in sit-
uations where PET shows an unusual involvement 
pattern in a patient with lymphoma, histological veri-
fication is still recommended, especially when the 
treatment decision relies on a confirmative diagnosis. 
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